Oxidoreductase (1. ) (e.g., Luciferase) Patents (Class 435/189)
  • Patent number: 8058417
    Abstract: Production and use of a sulfur-containing compound, tropodithietic acid (TDA), from the roseobacter Silicibacter sp. TM1040 is described. Specifically, a biosynthetic and regulatory pathway for TDA biosynthesis in roseobacters is described. The TDA produced from roseobacters, specifically Silicibacter sp. TM1040, is shown to have antibacterial activity, in particular against Vibrio anguillarium, Vibrio cholerae, Vibrio coralliilyticus, Vibrio shiloi, Halomonas spp., Mycobacterium marinum, Mycobacterium tuberculosis, Pseudomonas elongate, Spongiobacter nikelotolerans, and Staphylococcus aureus (MRSA).
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: November 15, 2011
    Inventors: Robert Belas, Haifeng Geng, Ryan Powell
  • Patent number: 8058034
    Abstract: A D-aminotransferase can be modified so as to efficiently produce (2R,4R)-monatin having high sweetness intensity from 4-(indol-3-ylmethyl)-4-hydroxy-2-oxoglutaric acid by substituting an amino acid at least at one of positions (positions 100, 180 to 183, 243 and 244) involved in efficiently producing the (2R,4R)-monatin in an amino acid sequence of a wild-type D-aminotransferase represented in SEQ ID NO:2.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: November 15, 2011
    Assignee: Ajinomoto Co., Inc.
    Inventors: Masakazu Sugiyama, Kunihiko Watanabe, Tatsuki Kashiwagi, Ei-ichiro Suzuki
  • Publication number: 20110275536
    Abstract: The application discloses Quiescin Q6 as a new biomarker for acute heart failure; methods for predicting, diagnosing and/or prognosticating acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: January 28, 2010
    Publication date: November 10, 2011
    Applicant: Pronota N.V.
    Inventor: Koen Kas
  • Publication number: 20110275135
    Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for modulating or altering recombination inside or outside of a cell using isolated and/or purified polypeptides and/or nucleic acid sequences from Alicyclobacillus acidocaldarius.
    Type: Application
    Filed: May 5, 2010
    Publication date: November 10, 2011
    Applicant: Battelle Energy Alliance, LLC
    Inventors: Brady D. Lee, Deborah T. Newby, Jeffrey A. Lacey, David N. Thompson, Vicki S. Thompson, William A. Apel, Francisco F. Roberto, David W. Reed
  • Publication number: 20110277043
    Abstract: The present invention relates to polynucleotides from Cochliobolus heterostrophus C5, Cyanothece sp. CCY0110, Mycocentrospora acerina and Hyaloperonospora parasitica, which code for desaturases and which can be employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors, host cells and transgenic nonhuman organisms which comprise the polynucleotides according to the invention, and to the polypeptides encoded by the polynucleotides. The invention furthermore relates to antibodies against the polypeptides according to the invention. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions and to their use as drugs, cosmetics, foodstuffs, feedstuffs, preferably fish food, or food supplements.
    Type: Application
    Filed: December 8, 2009
    Publication date: November 10, 2011
    Applicant: BASF Plant Science Company GmbH
    Inventors: Toralf Senger, Jörg Bauer, Johnathan A. Napier
  • Publication number: 20110274673
    Abstract: The present disclosure relates to a strain of Bacillus amyloliquefaciens bacteria that hyperproduces amylase enzyme and protease enzyme. The strain is also suitable for producing lipase for the degradation of oleaginous materials such as fats, greases and cooking oils. The strain also has excellent fungicidal and/or fungistatic qualities. The strain of the present disclosure and the enzymes produced thereby have a number of applications, including agricultural uses, laundry and dish detergents, drain cleaners and spot removers, and among other things, baking applications.
    Type: Application
    Filed: May 3, 2011
    Publication date: November 10, 2011
    Applicant: Novozymes Biologicals, Inc.
    Inventors: Yaowei Kang, Shawn Semones, Jessica Smith, Michael Frodyma
  • Publication number: 20110269210
    Abstract: Disclosed are compositions comprising variants of alpha-amylase that have alpha-amylase activity and that exhibit altered properties relative to a parent AmyS-like alpha-amylase from which they are derived. The compositions generally comprise at least one of an additional enzyme, a detergent,.a surfactant, a chelator, an oxidizing agent, an acidulant, an alkalizing agent, a source of peroxide, a source of hardness, a salt, a detergent complexing agent, a polymer, a stabilizing agent, or a fabric conditioner. Also disclosed are detergent formulations comprising the variants. Methods of using the compositions for desizing woven material and washing or cleaning items, such as dishes or laundry, are disclosed. Kits related thereto are also provided.
    Type: Application
    Filed: June 2, 2011
    Publication date: November 3, 2011
    Applicant: Danisco US Inc.
    Inventor: Mee-Young Yoon
  • Publication number: 20110271400
    Abstract: Phakopsora pachyrhizi, the fungal pathogen that causes Asian soybean rust, has the potential to cause significant losses in soybean yield in many production regions of the U.S. To assist the development of new modes of soybean resistance to fungal infection, peptides were identified from combinatorial phage-display peptide libraries which inhibit germ tube growth from urediniospores of P. pachyrhizi. Two peptides, Sp2 and Sp39, were identified that inhibit germ tube development when displayed as fusions with the coat protein of M13 phage or as fusions with maize cytokinin oxidase/dehydrogenase (ZmCKX1). These peptides may be used in vitro to help control fungal infection.
    Type: Application
    Filed: April 30, 2011
    Publication date: November 3, 2011
    Inventors: Zhiwei Fang, James T. English, James E. Schoelz, Francis J. Schmidt
  • Patent number: 8048647
    Abstract: The present invention relates to a method for producing optically active IHOG, which can in turn be used for the production of monatin. The present invention further relates to a method for producing optically active monatin, and aldolase used for these methods. As such, the present invention enables the synthesis of 4-(Indole-3-ylmethyl)-4-hydroxy-2-oxoglutaric acid with high optical purity, which is useful as an intermediate in the synthesis of optically active monatin, from indole pyruvic acid and pyruvic acid (or oxaloacetic acid).
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: November 1, 2011
    Assignee: Ajinomoto Co., Inc.
    Inventors: Masakazu Sugiyama, Kunihiko Watanabe, Kenichi Mori, Hiroyuki Nozaki
  • Publication number: 20110262974
    Abstract: The present invention relates to novel polypeptides according to caroase 01-05 or any functional equivalents of any of them, suitable for use in a method for preparing a food products having increased whiteness, the use of the enzyme to increase whiteness of at least part of a food product, a process for preparing a food product wherein the enzyme is used and the food product obtained.
    Type: Application
    Filed: June 3, 2011
    Publication date: October 27, 2011
    Applicant: DSM IP ASSETS B.V.
    Inventors: Holger Zorn, Manuela Scheibner, Bärbel Hulsdau, Ralf Günter Berger, Lex De Boer, Roelf Bernhard Meima
  • Publication number: 20110262978
    Abstract: An expression vector capable of expressing a foreign gene in Pseudonocardia autotrophica; a transformant of Pseudonocardia autotrophica produced by using the expression vector; a method for producing a protein by using the transformant; a method for producing an active form of vitamin D3 from vitamin D3, which comprises highly expressing a gene encoding an enzyme involved in the synthesis of the active form of vitamin D3 in a transformant by using the expression vector or the transformant; a method for producing 25-hydroxyvitamin D2 from vitamin D2; and a method for producing pravastatin from compactin, which comprises highly expressing a compactin hydroxylase gene in a transformant by using the expression vector or the transformant.
    Type: Application
    Filed: October 5, 2009
    Publication date: October 27, 2011
    Applicant: MERCIAN CORPORATION
    Inventors: Yoshikazu Fujii, Tadashi Fujii, Akira Arisawa, Tomohiro Tamura
  • Publication number: 20110262451
    Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of isovaleryl-coenzyme A dehydrogenase (IVD), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.
    Type: Application
    Filed: May 7, 2009
    Publication date: October 27, 2011
    Inventors: Jérôme Aubert, Tony Minier, Valérie Trinquet, Michel Rivier
  • Publication number: 20110262954
    Abstract: The present invention relates to vectors for transforming archaea and to transformed archaea, and in particular to shuttle vector systems for transformation of members of the genus Pyrococcus.
    Type: Application
    Filed: March 15, 2011
    Publication date: October 27, 2011
    Applicant: UNIVERSITAT REGENSBURG
    Inventors: Michael Thomm, Winfried Hausner, Ingrid Waege
  • Patent number: 8043827
    Abstract: The present invention provides an “in vivo and in vitro real-time bioluminescence imaging means,” which can transmit a detection signal promptly in response to an external signal, while taking advantage of a single-molecule-format luminescent probe as a bioluminescent means. The present invention is characterized by using, as a single-molecule-format luminescent probe utilizing the increase and decrease of a second messenger level as an index, a fusion protein including a single-chain protein containing a second messenger recognition protein and optionally a peptide which is capable of binding with the protein, and linked respectively to the N-terminus and the C-terminus thereto, an N-terminal fragment (N-LE) and a C-terminal fragment (C-LE) generated by dissecting a luminescent enzyme (LE).
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: October 25, 2011
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Sung-Bae Kim, Hiroaki Tao, Moritoshi Sato
  • Publication number: 20110256544
    Abstract: The present invention provides MICAL and MICAL-Like polypeptides and polynucleotides. Also provided are methods that for identifying agents that affect axon growth and placement. Furthermore, provided herein are methods for affecting axon growth and placement.
    Type: Application
    Filed: September 15, 2010
    Publication date: October 20, 2011
    Inventors: Alex L. Kolodkin, Jon R. Terman, Tiany Mao, Ronald J. Pasterkamp, Hung-Hsiang Yu
  • Publication number: 20110256601
    Abstract: Bacteria consume a variety of biomass-derived substrates and produce ethanol. Hydrogenase genes have been inactivated m Thermoanaerobacterium saccharolyticum to generate mutant strains with reduced hydrogenase activities. One such mutant strain with both the ldh and hydtrA genes inactivated shows a significant increase in ethanol production. Manipulation of hydrogenase activities provides a new approach for enhancing substrate utilization and ethanol production by biomass-fermenting microorganisms.
    Type: Application
    Filed: December 17, 2008
    Publication date: October 20, 2011
    Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Arthur Josephus Shaw, IV, Lee Lynd, David A. Hogsett
  • Patent number: 8039237
    Abstract: Genetically engineered organisms for production of PHA copolymers containing 2-hydroxyacid monomers and the methods of making and using thereof have been developed. The copolymers containing 2-hydroxyacid monomers can be synthesized via biosynthesis by the action of a PHA polymerase in a living cell. By changing the genetic background of the cells, one can control specific metabolic pathways allowing control of the level of glycolic acid co-monomer in the PHA polymer.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: October 18, 2011
    Assignees: Metabolix, Inc., Tepha, Inc.
    Inventors: David P. Martin, Frank A. Skraly
  • Patent number: 8034593
    Abstract: The present invention concerns multimeric oxidoreductase complexes which function in the enzymatic conversion of a carbon substrate, said complexes having a dehydrogenase subunit and a cytochrome C subunit. The invention further relates to polynucleotides coding for the multimeric complexes and methods of use thereof.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: October 11, 2011
    Assignee: Danisco US Inc.
    Inventors: Robert M. Caldwell, M. Harunur Rashid, Fernando Valle
  • Patent number: 8034594
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: October 11, 2011
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Patent number: 8034384
    Abstract: A material includes a surface and a reactive agent that is located at the surface of the material, covalently attached to a backbone of the material, and/or located within the material. The reactive agent has nitrite reductase activity, nitrate reductase activity, and/or nitrosothiol reductase activity. The reactive agent also converts at least one of nitrites, nitrates and nitrosothiols to nitric oxide when in contact with blood. A reproducible nitrosothiol sensor is also disclosed.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: October 11, 2011
    Assignee: The Regents of The University of Michigan
    Inventors: Mark E. Meyerhoff, Melissa M. Reynolds, Megan Frost, Sangyeul Hwang, Yiduo Wu
  • Publication number: 20110244537
    Abstract: Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-position to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli, where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.
    Type: Application
    Filed: January 3, 2011
    Publication date: October 6, 2011
    Applicant: THE CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Frances H. Arnold, Matthew W. Peters, Peter Meinhold
  • Patent number: 8030017
    Abstract: Luciferase enzymes with greatly increased thermostability, e.g., at least half lives of 2 hours at 50° C., cDNAs encoding the novel luciferases, and hosts transformed to express the luciferases, are disclosed. Methods of producing the luciferases include recursive mutagenesis. The luciferases are used in conventional methods, some employing kits.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: October 4, 2011
    Assignee: Promega Corporation
    Inventors: Keith V. Wood, Monika G. Wood, Mary P. Hall
  • Publication number: 20110236940
    Abstract: Provided is a method of preparing piceatannol, and more particularly, to a method of preparing piceatannol from resveratrol using bacterial cytochrome P450 BM3 (CYP102A1) or mutants thereof, and a composition and a kit therefor.
    Type: Application
    Filed: April 10, 2009
    Publication date: September 29, 2011
    Applicant: GLO BIOTECH
    Inventors: Chul Ho Yun, Dong Hyun Kim
  • Patent number: 8026085
    Abstract: A method and system for selectively fluorinating organic molecules on a target site wherein the target site is activated and then fluorinated are shown together with a method and system for identifying a molecule having a biological activity.
    Type: Grant
    Filed: August 4, 2007
    Date of Patent: September 27, 2011
    Assignee: California Institute of Technology
    Inventors: Rudi Fasan, Frances H. Arnold
  • Patent number: 8026089
    Abstract: The present invention relates to mutant ?8 desaturase genes, which have the ability to convert eicosadienoic acid [20:2 ?-6, EDA] to dihomo-?-linolenic acid [20:3, DGLA] and/or eicosatrienoic acid [20:3 ?-3, ETrA] to eicosatetraenoic acid [20:3 ?-3, ETA]. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding ?8 desaturase along with methods of making long-chain polyunsaturated fatty acids (PUFAs) using these mutant ?8 desaturases in plants and oleaginous yeast are disclosed.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: September 27, 2011
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Howard Glenn Damude, Hongxian He, Der-Ing Liao, Quinn Qun Zhu
  • Publication number: 20110229776
    Abstract: Provided are an enzyme immobilizing method, a fuel cell and an electrode for the fuel cell which employ the enzyme immobilizing method, and a method for manufacturing the fuel cell and the electrode. The enzyme immobilizing method prevents reduction in enzyme activity when the enzyme is immobilized on the electrode, so as to make it possible to obtain a high catalyst current value. In the method for immobilizing an enzyme on the electrode used in the fuel cell, an enzyme variant with at least one amino acid residue being deleted, substituted, added, or inserted in a wild-type amino acid sequences is used as the enzyme, and the enzyme variant increases in activity through heat treatment. The immobilization is performed within a temperature range which makes it possible to increase the activity of the enzyme variant.
    Type: Application
    Filed: November 24, 2009
    Publication date: September 22, 2011
    Applicant: SONY CORPORATION
    Inventors: Hideyuki Kumita, Takaaki Nakagawa, Hideki Sakai, Masaya Kakuta, Yuichi Tokita
  • Publication number: 20110229955
    Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.
    Type: Application
    Filed: March 24, 2011
    Publication date: September 22, 2011
    Applicants: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California
    Inventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu
  • Patent number: 8021866
    Abstract: The present invention provides for design and therapeutic use of ADPase enhanced polypeptides, pharmaceutical compositions, and methods useful for preventing and reversing platelet aggregation and recruitment for the treatment and prevention of vascular disorders in mammals.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: September 20, 2011
    Assignee: APT Therapeutics, Inc.
    Inventors: Soon Seog Jeong, Ridong Chen, Timothy A. Mitsky
  • Patent number: 8022101
    Abstract: A method of treatment of native, non-denatured tissue to increase resistance to tearing, fissuring, rupturing, and/or delamination, comprising the step of: contacting at least a portion of the tissue with an effective amount of a reagent that increases crosslinks in the tissue.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: September 20, 2011
    Assignee: Orthopeutics, L.P.
    Inventor: Thomas P. Hedman
  • Publication number: 20110217279
    Abstract: The present invention is directed to methods of modulating PKC-? activity and PKC-?/ERK complex activity in cells via biliverdin reductase. Methods and compositions for diagnosing and treating a PKC-? and PKC-?/ERK complex related condition are also disclosed.
    Type: Application
    Filed: November 8, 2010
    Publication date: September 8, 2011
    Applicant: UNIVERSITY OF ROCHESTER
    Inventor: Mahin D. MAINES
  • Publication number: 20110217414
    Abstract: The present invention relates to isolated polypeptides having tyrosinase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing, activating and using the polypeptides.
    Type: Application
    Filed: September 16, 2008
    Publication date: September 8, 2011
    Applicant: Novozymes A/S
    Inventors: Kirk Matthew Schnorr, Jeppe Wegener Tams, Christel Thea Joergensen
  • Publication number: 20110217754
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize chiral compounds.
    Type: Application
    Filed: May 18, 2011
    Publication date: September 8, 2011
    Applicant: CODEXIS, INC.
    Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Rama Voladri, James LaLonde, Gjalt W. Huisman
  • Patent number: 8012725
    Abstract: The present invention relates to enzymic processes for preparing S-butan-2-ol; and to enzymes for carrying out said processes; to nucleic acid sequences coding for said enzymes, to expression cassettes, vectors and recombinant hosts containing said nucleic acid sequences.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: September 6, 2011
    Assignee: BASF SE
    Inventors: Rainer Stürmer, Bernhard Hauer, Dejana Drew, Michael Breuer, Hartwig Schröder
  • Patent number: 8012734
    Abstract: A Family 6 cellulase variant enzyme comprising one or more than one amino acid substitution selected from a basic, polar or non-polar amino acid at position 103, a valine or isoleucine at position 136, a tyrosine at position 186, a glutamic acid or glutamine at position 365 and a glutamine at position 410 is provided (said position determined form alignment of the parental Family 6 with SEQ ID NO: 1). Genetic constructs and genetically modified microbes comprising DNA sequences encoding the Family 6 cellulase variant are also provided. Family 6 cellulases of the invention display reduced inhibition by glucose relative to the parent Family 6 cellulases. Such cellulases find use in a variety of applications in industry, e.g., in the hydrolysis of pretreated lignocellulosic feedstock, that require cellulose activity in the presence glucose concentrations that would otherwise inhibit the activity of the parental enzyme.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: September 6, 2011
    Assignee: Iogen Energy Corporation
    Inventors: James A. Lavigne, Christopher M. D. Hill, Annie Tremblay, Patrick St-Pierre, John J. Tomashek
  • Publication number: 20110212111
    Abstract: The present invention provides a MHC II associated protein, MPYS, and methods for using the same. In particular, the MHC II-associated protein of the present invention mediates apoptosis and influences the susceptibility to infectious diseases. The present invention also provides methods for treating clinical conditions, methods for identifying therapeutically useful compounds using such a protein, and methods for determining susceptibility to infectious disease.
    Type: Application
    Filed: November 2, 2009
    Publication date: September 1, 2011
    Inventors: John C. Cambier, Lei Jin
  • Publication number: 20110212133
    Abstract: The present invention relates to novel diagnostic, prognostic and therapeutic reagents for infection of an animal subject such as a human by Pseudomonas aeruginosa, and conditions associated with such infections, such as, for example, an acute clinical exacerbation in a cystic fibrosis (CF) subject. In particular, the present invention relates to methods for diagnosing/prognosing an infection by P. aeruginosa in a subject comprising detecting the presence or amount of one or more proteins of P. aeruginosa or a fragment or epitope thereof or an antibody thereto in a sample from the subject.
    Type: Application
    Filed: February 3, 2011
    Publication date: September 1, 2011
    Inventors: Andrew John Sloane, Susanne Kartin Pedersen, Ron Weinberger
  • Publication number: 20110214204
    Abstract: The invention provides isolated pyruvate dehydrogenase kinase nucleic acids and their encoded polypeptides. The present invention provides methods and compositions relating to altering pyruvate dehydrogenase kinase levels in plants. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions.
    Type: Application
    Filed: May 12, 2011
    Publication date: September 1, 2011
    Applicant: EI DU PONT DE NEMOURS AND COMPANY; AND PIONEER HI-BRED INTERNATIONAL INC
    Inventors: Quinn Qun Zhu, Sabine S. Hantke, Xiping Niu, Zheng Peizhong, Michele Morgante, Joan T. Odell, Saverio Carl Falco, Yiwen Fang, J. Antoni Rafalski, Hajime Sakai, Edgar B. Cahoon, Rebecca E. Cahoon, Jian-Ming Lee, Guo-Hua Miao, Zhongsen Li, Anthony J. Kinney
  • Publication number: 20110212503
    Abstract: A method for designing a heat-resistant mutant enzyme, the method including the step of reducing a distance between the ?4 helix and the ?6 helix in a protein three-dimensional structure to become smaller than that of a wild type enzyme through deletion, replacement, addition, or insertion of one or several amino acids in the amino acid sequence of the wild type enzyme with respect to tyrosine-dependent short-chain dehydrogenase/reductase.
    Type: Application
    Filed: January 25, 2011
    Publication date: September 1, 2011
    Applicant: SONY CORPORATION
    Inventors: Daisuke Yamaguchi, Seiji Yamada, Yoshio Goto, Yuichi Tokita
  • Publication number: 20110212502
    Abstract: The invention relates to [NiFe]-hydrogenases having an improved resistance to dioxygen, said [NiFe]-hydrogenases may be obtained by:—providing an initial polynucleotide comprising a sequence encoding a large subunit of a [NiFe]-hydrogenase, said large subunit comprising the following peptide motifs: L1: RGXE, wherein X=L, I, F, V or M L2: [R/K]X1C[G/R]X2C, wherein Xi is any amino acid residue, X2=L, V, I or M; L1 and L2 being separated by 16 any amino acid residues; L3: X1X2X3X4X5X6X7X8X9X10X11X12[D/S/E], wherein X1=D, S, N or E, X2=H, D, S, N or L, X5=H, S, A, Q or W, X6=F, T, Y or G, X9=L, F, M or Y, the other Xn being any amino acid residue; L4: D[P/I/S]CX1X2CX3X4[H/R], wherein X2=A.S.V.G or T, X1, X3 and X4 are any amino acid residue and optionally comprising a motif LO: R[I/V/A]EG[H/D/A].—modifying said initial polynucleotide in order to substitute at least one of the residues X2 of motif L2 and Z or X4 of motif L3 and Z or X9 of motif L3 of said large subunit by a methionine.
    Type: Application
    Filed: August 1, 2008
    Publication date: September 1, 2011
    Inventors: Laurent Cournac, Anne Volbeda, Marc Rousset, Emeline Aubert-Jousset, Geneviève Guedeney, Sébastien Dementin, Christophe Leger, Fanny Leroux, Stéphanie Champ
  • Patent number: 8008006
    Abstract: A method to prepare synthetic nucleic acid molecules having reduced inappropriate or unintended transcriptional characteristics when expressed in a particular host cell.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: August 30, 2011
    Assignee: Promega Corporation
    Inventors: Keith V. Wood, Monika G. Wood, Brian Almond, Aileen Paguio, Frank Fan
  • Patent number: 8008461
    Abstract: The present invention is to provide a process for efficiently producing an optically active alcohol including (R)-3-hydroxy-3-phenylpropanenitrile. One of the features of the present invention is a polypeptide having an activity of asymmetrically reducing 3-oxo-3-phenylpropanenitrile isolated from a microorganism belonging to the genus Candida to produce (R)-3-hydroxy-3-phenylpropanenitrile, DNA encoding the polypeptide and a transformant of producing the polypeptide. Another feature of the present invention is a process for producing an optically active alcohol such as (R)-3-hydroxy-3-phenylpropanenitrile by reducing a carbonyl compound such as 3-oxo-3-phenylpropanenitrile by use of the polypeptide or the transformant.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: August 30, 2011
    Assignee: Kaneka Corporation
    Inventors: Noriyuki Kizaki, Makoto Ueda, Daisuke Moriyama, Naoaki Taoka, Yoshihiko Yasohara
  • Publication number: 20110206615
    Abstract: The present invention relates to fluorescent or luminescent probe reagents for measuring oxidative stress in a cell or an organism. Examples of the probe reagents include: a fluorescent or luminescent protein and a marker protein; a fluorescent or luminescent protein, a marker protein, and a regulatory factor; or a fluorescent or luminescent protein, a marker protein, a cleavage sequence, and a regulatory factor. In the probe reagents, the marker protein makes it possible to detect the oxidative stress caused by reactive oxygen species and comprises a regulatory factor-binding site and a ubiquitin-binding site; and the regulatory factor is a protein making it possible to regulate degradation of the marker protein in response to the reactive oxygen species. The present invention also relates to a method of measuring oxidative stress in a cell or an organism, or a method of screening a substance which suppresses or promotes the oxidative stress in a cell or an organism by using the probe reagent.
    Type: Application
    Filed: February 27, 2009
    Publication date: August 25, 2011
    Inventors: Atsushi Miyawaki, Kazuki Sasaki
  • Patent number: 8003359
    Abstract: Disclosed are: a eukaryotic amadoriase which is prepared by introducing a mutation into DNA encoding a eukaryotic amadoriase derived from a microorganism belonging to the genus Coniochaeta or Eupenicillium so as to introduce a substitution into a specific amino acid residue in the eukaryotic amadoriase, thereby overcoming the defect associated with thermal stability; a gene or recombinant DNA for the eukaryotic amadoriase; and a process for production of a eukaryotic amadoriase having excellent thermal stability.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: August 23, 2011
    Assignee: Kikkoman Corporation
    Inventors: Kozo Hirokawa, Atsushi Ichiyanagi
  • Patent number: 8003358
    Abstract: The present invention discloses a two-step enzyme method for preparing 7-aminocephalosporanic acid from cephalosporin C, wherein D-amino acid oxidase used is purified D-amino acid oxidase mutant of yeast Trigonopsis variabilis, having a specific activity of 105% higher than that of parent D-amino acid oxidase. The method has no need of addition of hydrogen peroxide, ?-lactamase inhibitor, catalase inhibitor, catalase and the like commonly used in the prior art. The productivity of the method can reach more than 93%. Thus, the method is simple, low in cost and high in productivity.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: August 23, 2011
    Assignee: Bioright Worldwide Company Limited
    Inventors: Jun Wang, Waikei Tsang, Hongkin Yap, Junmin Chen, Yaulung Siu, Supyin Tsang
  • Publication number: 20110201082
    Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Application
    Filed: April 25, 2011
    Publication date: August 18, 2011
    Applicant: Novozymes A/S
    Inventors: Katja Salomon Johansen, Keith Gibson, Preben Nielsen, Helle Outtrup
  • Publication number: 20110201081
    Abstract: Provided herein are variants of Buttiauxella sp. phytases that may be used in industrial applications including methods for starch liquefaction, alcohol fermentations and for enhancing phosphate digestion in foods and animal feeds.
    Type: Application
    Filed: April 17, 2009
    Publication date: August 18, 2011
    Inventors: Oliver Kensch, Klaus Schulze Pellengahr, Birgitta Leuthner, Jayarama K. Shetty, Michael Pepsin, Søren Dalsgaard, Mai Faurschou Isaksen
  • Patent number: 7998970
    Abstract: The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: August 16, 2011
    Assignee: ProteoSys AG
    Inventors: Vukic Soskic, André Schrattenholz
  • Publication number: 20110195444
    Abstract: The present invention provides: a protein having a fructosyl amino acid oxidase activity which protein is useful for measurement of a glycosylated protein (particularly, glycosylated hemoglobin); a modified protein thereof; and use of the protein or the modified protein. The protein of the present invention is, for example, a fructosyl valyl histidine oxidase derived from Phaeosphaeria nodorum, the fructosyl valyl histidine oxidase having excellent thermal stability and substrate specificity and also having a small Km value to fructosyl valyl histidine. This allows a glycosylated protein measuring reagent to be stored in a long time and measurement accuracy of the glycosylated protein measuring reagent to be improved.
    Type: Application
    Filed: October 6, 2009
    Publication date: August 11, 2011
    Applicants: TOYO BOSEKI KABUSHIKI KAISHA, GEKKEIKAN SAKE CO., LTD.
    Inventors: Rie Hirao, Masao Kitabayashi, Yoshiaki Nishiya, Hiroki Ishida, Yoji Hata
  • Publication number: 20110195422
    Abstract: Methods for determining the efficiency of a therapeutic. In at least one embodiment of a method of determining the efficacy of a therapeutic compound, the method comprises the steps of treating a subject having a disease state with an effective amount of therapeutic compound, harvesting at least one cell from the subject following a treatment with the therapeutic compound, bringing the at least one cell into contact with a stabilizing compound capable of completely or substantially preventing the degradation or inactivation of a diagnostic marker for the disease state, analyzing the at least one stabilized cell for the at least one diagnostic marker, creating a marker profile from at least one result determined from analyzing the at least one stabilized cell, and comparing the marker profile with at least one previous marker profile to determine efficacy of the therapeutic compound on the disease state.
    Type: Application
    Filed: October 18, 2010
    Publication date: August 11, 2011
    Inventors: Richard H. Selinfreund, Rakesh Vig, Richard P. Gill
  • Publication number: 20110195465
    Abstract: The present disclosure provides ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, method of using the engineered ketoreductase enzymes to synthesize a variety of chirally pure compounds, and the chirally pure compounds prepared therewith.
    Type: Application
    Filed: December 23, 2010
    Publication date: August 11, 2011
    Applicant: CODEXIS, INC.
    Inventors: Lorraine Joan Giver, Lisa Marie Newman, Emily Mundorff, Gjalt W. Huisman, Stephane J. Jenne, Jun Zhu, Behnaz Behrouzian, John H. Grate, James Lalonde